DNA Vaccines 2010, March 2 - 4, 2010, New Orleans, LA
DNA Vaccines 2010 will be held March 2 - 4, 2010, at Sheraton New Orleans Hotel, New Orleans, LA. This meeting will follow the same successful pattern as the prior meeting for leading researcher to gather and report on the latest cutting edge research currently being undertaken in the progressive field of DNA or [...]
Leukemia Vaccine Shows Promise
BioSante Pharmaceuticals, Inc. announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate). BioSante owns the commercial rights to all GVAX vaccines as a result [...]
Cell-based Viral Vaccines: FDA Issues Final Guidance
To boost development of cell-based viral vaccines FDA issued final guidance. Today’s guidance outlines the best practices using current and emerging science to safely expand the types of cells that may be used to produce vaccines.
According to a recent market study “Global Pandemic Influenza Preparedness Market Forecast 2010-2015“, cell-based development will be the core of [...]
Anthrax Vaccine Contract for $78.4 Awarded by HHS
A biodefense company PharmAthene, Inc., specializing in the development and commercialization of medical countermeasures against chemical and biological threats, has been awarded additional contract for $78.4 by Department of Health and Human Services (HHS) to develop a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National [...]
Pneumococcal Disease Vaccine Approved by FDA
Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years, has been approved by FDA. The new vaccine extends the protection to six additional types of the disease causing bacteria. Prevnar 13 is the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in [...]
Gates Foundation Will Commit $10 Billion for Vaccine Development
Gates Foundation announced commitment of $10 billion over the next decade to help research, develop and deliver vaccines for the world’s poorest countries. The foundation used a model developed by a consortium led by the Institute of International Programs at the Johns Hopkins Bloomberg School of Public Health to project the potential impact of vaccines [...]
Government Commission Calls for Faster Vaccine Production Technologies
President Barack Obama declared H1N1 a national emergency this weekend, a status that will give the federal government greater flexibility and authority to contain the pandemic. But the current shortage of H1N1 vaccine underscores the severe lack of U.S. preparedness in responding to pandemics, whether through natural disease transmission or manmade bioterrorist attacks.
“Whether the threat [...]
Low Vaccination Rates Force Governments to Cancel H1N1 Flu Vaccine Orders
Just a few month ago a forecast made by analysts of Market Research Media Ltd seemed to undermine impact of the H1N1 pandemic on the vaccine market - according to this market research report “Global Pandemic Influenza Preparedness Market Forecast 2010-2015” the worldwide government spending on Pandemic Influenza Preparedness would grow at rather moderate rate [...]
Influenza Vaccine Adjuvant to Improve Effectiveness of Flu Vaccine for Elders
Juvaris BioTherapeutics, Inc., a biotech company developing adjuvanted vaccines for infectious diseases, has begun enrolling patients in a Phase 2 clinical trial of JVRS-100, an adjuvant for seasonal influenza vaccines in the elderly population. Seasonal influenza affects approximately one billion people worldwide each year resulting in 5 million severe illnesses and 500,000 deaths. Approximately 90 [...]
New Joint Venture To Build Asia’s Largest Influenza Vaccine Facility
Microbix, (TSX:MBX) a Canadian developer of a patented technology that increases influenza vaccine yields, has signed a joint venture agreement with the Hunan Biopharmaceutical Co. Ltd. (a Chinese Hunan Province state-owned enterprise) for initial financing to build Asia’s largest influenza vaccine production facility and the third largest vaccine plant in the world. A newly formed [...]
